Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2-methyl-2-(4-(3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydroimidazo(4,5-c)quinolin-1-yl)phenyl)propanenitrile
2. 2-methyl-2-(4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-1h-imidazo(4,5-c)quinolin-1-yl)phenyl)propanenitrile
3. Bez235
4. Nvp Bez235
5. Nvp-bez235
6. Nvpbez235
1. 915019-65-7
2. Nvp-bez235
3. Bez235
4. Nvp-bez 235
5. Bez-235
6. 2-methyl-2-(4-(3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-1h-imidazo[4,5-c]quinolin-1-yl)phenyl)propanenitrile
7. Nvpbez235
8. Bez 235
9. Nvp-bez-235
10. Nvp Bez235
11. Bez235 (nvp-bez235)
12. Rtb101
13. Rtb-101
14. Ruj6z9y0dt
15. Nsc-751249
16. Bez235 (nvp-bez235, Dactolisib)
17. Chebi:71952
18. 915019-65-7 (free Base)
19. 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile
20. S1009
21. 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-ylimidazo[4,5-c]quinolin-1-yl)phenyl]propanenitrile
22. Nvp-bez235-nx
23. 2-methyl-2-(4-(3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydroimidazo(4,5-c)quinolin-1-yl)phenyl)propanenitrile
24. 2-methyl-2-[4-[3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydroimidazo[4,5-c]quinolin-1-yl]phenyl]propionitrile.
25. 2-methyl-2-{4-[3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-1h-imidazo[4,5-c]quinolin-1-yl]phenyl}propanenitrile
26. Dactolisib [usan]
27. Dactolisib [usan:inn]
28. Unii-ruj6z9y0dt
29. Bez235(nvp-bez235)
30. 2-methyl-2-(4-(3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydroimidazo[4,5-c]quinolin-1-yl)phenyl)propanenitrile
31. 2-methyl-2-[4-[3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydroimidazo[4,5-c]quinolin-1-yl]phenyl]propionitrile
32. Kinome_2911
33. Ct-bez
34. Dactolisib (bez235)
35. Dactolisib; Bez-235
36. Dactolisib [inn]
37. Dactolisib (usan/inn)
38. Nvp-bez235, Free Base
39. Mtor Inhibitor, Bez235
40. Dactolisib [who-dd]
41. Schembl143623
42. Gtpl7950
43. Chembl1879463
44. Bdbm92862
45. Amy2877
46. Dtxsid10238599
47. Ex-a404
48. Bcpp000344
49. Hms3244g21
50. Hms3244g22
51. Hms3244h21
52. Hms3672e19
53. Act04718
54. Bcp00216
55. Bez235 - Nvp-bez235
56. Mfcd10565944
57. Nsc751249
58. Nsc755807
59. Nsc800085
60. Zinc24760115
61. Akos005217097
62. Bcp9000397
63. Ccg-207981
64. Cs-0080
65. Db11651
66. Es-0038
67. Nsc 751249
68. Nsc-755807
69. Nsc-800085
70. Pb26555
71. 2-methyl-2-[3-methyl-2-oxo-8-(3-quinolinyl)-1-imidazo[4,5-c]quinolinyl]propanenitrile
72. Dactolisib (bez235, Nvp-bez235)
73. Ncgc00187481-01
74. Ncgc00187481-02
75. Ncgc00187481-04
76. Ncgc00187481-05
77. Ncgc00187481-06
78. Ncgc00187481-15
79. 2-(4-(2,3-dihydro-3-methyl-2-oxo-8-(quinolin-3-yl)imidazo[4,5-c]quinolin-1-yl)phenyl)-2-methylpropanenitrile
80. 2-methyl-2-(4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-1h-imidazo(4,5-c)quinolin-1-yl)phenyl)propanenitrile
81. Ac-25486
82. Hy-50673
83. Ft-0658563
84. Ec-000.2325
85. D10552
86. J-509915
87. Q4835503
88. Brd-k12184916-001-01-4
89. 1028385-31-0
90. 2-methyl-2-(4-(3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)phenyl)propionitrile
91. 2-methyl-2-[4-[3-methyl-2-oxo-8-(3-quinolyl)imidazo[4,5-c]quinolin-1-yl]phenyl]propanenitrile
92. 4-[2,3-dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1h-imidazo[4, 5-c]quinolin-1-yl]-.alpha.,.alpha.-dimethylbenzeneacetonitrile
93. Benzeneacetonitrile, 4-(2,3-dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1h-imidazo(4,5-c)quinolin-1-yl)-alpha,alpha-dimethyl-
Molecular Weight | 469.5 g/mol |
---|---|
Molecular Formula | C30H23N5O |
XLogP3 | 5.2 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 3 |
Exact Mass | 469.19026037 g/mol |
Monoisotopic Mass | 469.19026037 g/mol |
Topological Polar Surface Area | 73.1 Ų |
Heavy Atom Count | 36 |
Formal Charge | 0 |
Complexity | 872 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
ABOUT THIS PAGE
A Dactolisib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Dactolisib, including repackagers and relabelers. The FDA regulates Dactolisib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Dactolisib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Dactolisib supplier is an individual or a company that provides Dactolisib active pharmaceutical ingredient (API) or Dactolisib finished formulations upon request. The Dactolisib suppliers may include Dactolisib API manufacturers, exporters, distributors and traders.
Dactolisib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Dactolisib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Dactolisib GMP manufacturer or Dactolisib GMP API supplier for your needs.
A Dactolisib CoA (Certificate of Analysis) is a formal document that attests to Dactolisib's compliance with Dactolisib specifications and serves as a tool for batch-level quality control.
Dactolisib CoA mostly includes findings from lab analyses of a specific batch. For each Dactolisib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Dactolisib may be tested according to a variety of international standards, such as European Pharmacopoeia (Dactolisib EP), Dactolisib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Dactolisib USP).
LOOKING FOR A SUPPLIER?